Loading...
Emcure Pharmaceuticals Limited — Escitalopram Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #15 for Escitalopram · $2.1M export value · DGFT Verified
Emcure Pharmaceuticals Limited is the #15 Indian exporter of Escitalopram with $2.1M in export value and 145 verified shipments. Emcure Pharmaceuticals Limited holds a 1.1% market share in Escitalopram exports across 1 countries. The company exports 39 pharmaceutical products worth $147.8M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $37.9M | 758 | 39.4% |
| AUSTRALIA | $8.3M | 198 | 8.6% |
| CANADA | $7.7M | 344 | 8.1% |
| POLAND | $6.9M | 202 | 7.2% |
| BRAZIL | $5.9M | 125 | 6.2% |
| MOROCCO | $5.7M | 113 | 5.9% |
| MALTA | $4.3M | 489 | 4.4% |
| SOUTH AFRICA | $4.1M | 92 | 4.3% |
| BELGIUM | $4.1M | 333 | 4.2% |
| FINLAND | $2.2M | 84 | 2.3% |
India exports Escitalopram to 95 countries. The top destination is UNITED STATES (39.4%), followed by AUSTRALIA and CANADA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TORRENT PHARMA INC | UNITED STATES | $4.2M | 83 |
| LEK S.A. | POLAND | $4.1M | 112 |
| CIPLA MAROC | MOROCCO | $3.5M | 71 |
| RISING PHARMA HOLDINGS, INC. | UNITED STATES | $3.1M | 174 |
| AUROLOGISTICS LLC (AUROBINDO PHARMA | UNITED STATES | $2.9M | 57 |
India exported $109.7M worth of Escitalopram through 5,457 shipments from 231 suppliers to 95 countries, serving 628 buyers globally. Emcure Pharmaceuticals Limited contributes $2.1M to this total, accounting for 1.1% of India's Escitalopram exports.
Emcure Pharmaceuticals Limited's average Escitalopram shipment value is $14.3K per consignment, based on 145 shipments totaling $2.1M.
Emcure Pharmaceuticals Limited ranks #15 among 231 Indian Escitalopram exporters with a 1.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($22.5M), SANDOZ PRIVATE LIMITED ($12.9M), TORRENT PHARMACEUTICALS LTD ($12.1M). Emcure Pharmaceuticals Limited processed 145 shipments to 1 destination countries.
What Emcure Pharmaceuticals Limited must comply with to export Escitalopram to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #15 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | APOTEX RESEARCH PRIVATE LIMITED | $2.4M | 86 | 1 | $28.1K |
| 14 | MACLEODS PHARMACEUTICALS LTD | $2.2M | 107 | 13 | $20.8K |
| 15 | EMCURE PHARMACEUTICALS LIMITED ★ | $2.1M | 145 | 1 | $14.3K |
Emcure Pharmaceuticals Limited ranks #15 among 231 Indian Escitalopram exporters. Average shipment value of $14.3K compared to the market average of $474.7K. The closest competitors by value are APOTEX RESEARCH PRIVATE LIMITED and MACLEODS PHARMACEUTICALS LTD.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 652 | 11.9% |
| SAHAR AIR | 555 | 10.2% |
| NHAVA SHEVA SEA (INNSA1) | 471 | 8.6% |
| HYDERABAD ICD | 369 | 6.8% |
| DELHI AIR CARGO ACC (INDEL4) | 303 | 5.6% |
| DELHI AIR | 287 | 5.3% |
| HYDERABAD ICD (INSNF6) | 243 | 4.5% |
| HYDERABAD AIR | 217 | 4.0% |
Emcure Pharmaceuticals Limited also exports these cns & psychiatric products. Each links to the detailed product page.
Emcure's extensive export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic adjustments in logistics and supply chain management to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have opened opportunities for Indian pharmaceutical companies like Emcure to expand their footprint in the US market. The US's inclination to diversify its supply chain away from China presents a favorable environment for Indian exporters to increase their market share.
In the European Union, stringent regulatory changes, such as the Falsified Medicines Directive, impose additional compliance requirements on exporters. Emcure's adherence to these regulations is crucial for maintaining and expanding its presence in the EU market.
Compliance with international regulatory standards is paramount for Emcure's export operations. The company has consistently met the Good Manufacturing Practice (GMP) requirements set by the FDA, WHO, and EU authorities. However, the evolving regulatory landscape demands continuous investment in quality assurance and compliance mechanisms to ensure uninterrupted market access.
Recent incidents, such as the brief shutdown of the Pune plant due to a fire, highlight the importance of robust risk management and compliance strategies to maintain operational continuity and regulatory adherence. (tipranks.com)
Emcure Pharmaceuticals Limited exports 39 products worth $147.8M. Beyond Escitalopram, top products include Dolutegravir, Mycophenolate, Tenofovir, Iron, Melphalan. View the complete Emcure Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Escitalopram — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Emcure Pharmaceuticals Limited's Escitalopram exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Emcure Pharmaceuticals Limited
Full Company Profile →
39 products · $147.8M total trade · 19 categories
| AUROLOGISTICS LLC, (AUROBINDO PHARM |
| UNITED STATES |
| $1.8M |
| 35 |
| AUROLOGISTICS LLC | UNITED STATES | $1.7M | 34 |
| AUROLOGISTICS LLC AUROBINDO PHARM | UNITED STATES | $1.4M | 28 |
| TORRENT PHARMA INC IMPORTER EIN 36-4547412 | UNITED STATES | $1.3M | 26 |
| ACCORD HEALTHCARE C/O UPD LEA GLEN | SOUTH AFRICA | $1.1M | 22 |
India's Escitalopram is purchased by 628 buyers worldwide. The top buyer is TORRENT PHARMA INC (UNITED STATES), followed by LEK S.A. and CIPLA MAROC.
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 95+ countries, 628+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Emcure Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Escitalopram. For current shipment-level data, contact TransData Nexus.